LAIR-1 limits neutrophilic airway inflammation

Kuldeep Kumawat, Ruben J. Geerdink, Marije P. Hennus, Mojtaba Abdul Roda, Ingrid Van Ark, Thea Leusink-Muis, Gert Folkerts, Anita Van Oort-Jansen, Alexandra Mazharian, Steve P. Watson, Frank E. Coenjaerts, Louis Bont*, Linde Meyaard

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Neutrophils are crucial to antimicrobial defense, but excessive neutrophilic inflammation induces immune pathology. The mechanisms by which neutrophils are regulated to prevent injury and preserve tissue homeostasis are not completely understood. We recently identified the collagen receptor leukocyte-associated immunoglobulin-like receptor (LAIR)-1 as a functional inhibitory receptor on airway-infiltrated neutrophils in viral bronchiolitis patients. In the current study, we sought to examine the role of LAIR-1 in regulating airway neutrophil responses in vivo. LAIR-1-deficient (Lair1-/-) and wild-type mice were infected with respiratory syncytial virus (RSV) or exposed to cigarette smoke as commonly accepted models of neutrophil-driven lung inflammation. Mice were monitored for cellular airway influx, weight loss, cytokine production, and viral loads. After RSV infection, Lair1-/- mice show enhanced airway inflammation accompanied by increased neutrophil and lymphocyte recruitment to the airways, without effects on viral loads or cytokine production. LAIR-1-Fc administration in wild type mice, which blocks ligand induced LAIR-1 activation, augmented airway inflammation recapitulating the observations in Lair1-/- mice. Likewise, in the smoke-exposure model, LAIR-1 deficiency enhanced neutrophil recruitment to the airways and worsened disease severity. Intranasal CXCL1-mediated neutrophil recruitment to the airways was enhanced in mice lacking LAIR-1, supporting an intrinsic function of LAIR-1 on neutrophils. In conclusion, the immune inhibitory receptor LAIR-1 suppresses neutrophil tissue migration and acts as a negative regulator of neutrophil-driven airway inflammation during lung diseases. Following our recent observations in humans, this study provides crucial in-vivo evidence that LAIR-1 is a promising target for pharmacological intervention in such pathologies.

Original languageEnglish
Article number842
JournalFrontiers in Immunology
Volume10
Issue numberAPR
DOIs
Publication statusPublished - 26 Apr 2019

Funding

Kartika Padhan, National Institutes of Health (NIH), United States Giulia Fabozzi, National Institute of Allergy and Infectious Diseases (NIAID), United States 1Laboratory for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Oncode Institute, University Medical Center Utrecht, Utrecht, Netherlands, 3Department of Pediatric Intensive Care, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands, 4Division of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands, 5Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 6Centre of Membrane Proteins and Receptors, Universities of Birmingham and Nottingham, Birmingham, United Kingdom, 7Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands, 8Department of Pediatrics, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands Conflict of Interest Statement: LB and LM have regular interaction with pharmaceutical and other industrial partners. They have not received personal fees or other personal benefits. LB’s institute has received major funding (>e100,000 per industrial partner) for investigator-initiated studies from AbbVie, MedImmune, Janssen, the Bill and Melinda Gates Foundation and MeMed Diagnostics. LB’s institute has received minor funding participation in trials by Regeneron and Janssen since 2015 (total annual estimate <e20,000). LB received minor funding for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria Nordic, MabXience, Novavax, Janssen (total annual estimate <e20,000). LM’s institute has received funding for investigator-initiated studies from Nextcure, Boehringer Ingelheim, Ono Pharmaceuticals, Ablynx and Janssen. LM received minor funding for consultation from Novo Nordisk, Biogen and Boehringer Ingelheim.

Keywords

  • Airway
  • Bronchiolitis
  • Cigarette smoke
  • Inflammation
  • LAIR-1
  • Neutrophils
  • RSV

Fingerprint

Dive into the research topics of 'LAIR-1 limits neutrophilic airway inflammation'. Together they form a unique fingerprint.

Cite this